Type of Cancer
Phase
Division (Location)
Study ID
NCT#
Brief Description
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogenic stem cell transplantation
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.